Last $3.83 USD
Change Today +0.21 / 5.80%
Volume 421.7K
CORT On Other Exchanges
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

corcept therapeutics inc (CORT) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/3/14 - $4.49
52 Week Low
08/19/13 - $1.47
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

corcept therapeutics inc (CORT) Related Bloomberg News

View More Bloomberg News

corcept therapeutics inc (CORT) Related Businessweek News

No Related Businessweek News Found

corcept therapeutics inc (CORT) Details

Corcept Therapeutics Incorporated, a pharmaceutical company, is engaged in the discovery, development, and commercialization of drugs for the treatment of metabolic, psychiatric, and oncologic disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing mifepristone, an active ingredient in Korlym, which is in Phase III study for treatment of the psychotic features of psychotic depression; and in Phase I study for the treatment of triple-negative breast cancer. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited; Sygnature Discovery Limited; ICON Clinical Research, L.P.; and MedAvante, Inc. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

44 Employees
Last Reported Date: 03/14/14
Founded in 1998

corcept therapeutics inc (CORT) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $925.9K
Chief Financial Officer and Secretary
Total Annual Compensation: $465.4K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $582.6K
Chief Accounting Officer, Vice President and ...
Total Annual Compensation: $328.2K
Total Annual Compensation: $679.0K
Compensation as of Fiscal Year 2013.

corcept therapeutics inc (CORT) Key Developments

Corcept Therapeutics Incorporated Enters Manufacturing Agreement with Aaipharma Services Corp. to Supply Mifepristone

Corcept Therapeutics Incorporated into a manufacturing agreement with AAIPharma Services Corp. (AAI), pursuant to which AAI will manufacture and package Korlym tablets (the product). The company will supply mifepristone, the active pharmaceutical ingredient in Korlym, to AAI for use in the manufacture of the product. The initial term of the agreement is a period of three years from April 7, 2014, with consecutive automatic extensions of two years unless either party gives written notice-in the case of AAI, 18 months prior to the end of the applicable term, and in case 12 months prior to the end of the applicable term-that it does not want such an extension. The company have the right to terminate the agreement if AAI is unable to manufacture the product for a consecutive four-month period or if the product is withdrawn from the market.

Corcept Therapeutics Provides Update on Phase I Clinical Study of Mifepristone

Corcept Therapeutics announced that two sites affiliated with US Oncology Research will participate in Corcept's multi-center, Phase I clinical study of mifepristone in combination with chemotherapy drug eribulin (Halaven(R)) in patients with metastatic or locally advanced unresectable breast cancer. Up to 20 patients with metastatic breast cancer will be eligible to enroll in the first phase of the study, which will determine the maximum tolerated dose of the mifepristone - eribulin combination. Up to an additional 20 patients with glucocorticoid receptor-positive metastatic triple-negative breast cancer will be enrolled into a subsequent expansion phase. This portion of the study will include efficacy endpoints. The US Oncology Research participating sites include Texas Oncology - Baylor Charles A. Sammons Cancer Center, led by principal investigator Carlos Becerra, M.D. and Virginia Cancer Specialists, led by Alex Spira, M.D., PhD, F.A.C.P. Triple-negative breast cancer is a form of the disease in which the three receptors that fuel most breast cancer growth -- estrogen, progesterone, and the HER-2/neu gene -- are not present. Since the tumor cells lack the necessary receptors, common treatments, such as hormone therapy and drugs that target estrogen, progesterone, and HER-2, are ineffective.

Corcept Therapeutics Seeks Acquisitions

Corcept Therapeutics Incorporated (NasdaqCM:CORT) looks for acquisitions. Corcept Therapeutics has filed for shelf registration in the amount of $100 million, a portion of the net proceeds will be used to acquire or invest in businesses, products and technologies that are complementary to Corcept Therapeutics' own, although it currently has no plans, commitments or agreements with respect to any such acquisitions or investments.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CORT:US $3.83 USD +0.21

CORT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Novartis AG SFr.74.70 CHF +0.35
View Industry Companies

Industry Analysis


Industry Average

Valuation CORT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 34.9x
Price/Book 17.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 26.5x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CORCEPT THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at